Status: open
Boehringer Ingelheim and Teva Pharmaceutical (Aggrenox)
Defendant: Boehringer Ingelheim and Teva Pharmaceutical
Consumers who bought certain dosages of Aggrenox and/or its generic version between November 30, 2009 and December 22, 2017 may be eligible for payment. The company reached a settlement over allegations of antitrust violations.